NEW YORK (GenomeWeb) – China's BGI said this week that it has received a CLIA certificate of registration for its Hong Kong laboratory.
BGI said the certification will help it to expand its offering of clinical sequencing services for specific diseases, including cancer and Mendelian disorders. It will also be useful for genomics-based clinical trial testing as part of BGI's CRO pharma solutions, which support drug discovery and development for biopharmaceutical clients.
The company's Hong Kong laboratory was established in 2010 and was accredited by the College of American Pathologists in 2013. It currently serves as BGI's largest sequencing and logistics center for international customers.